Amgen AMGN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $7.8B+1.2% | $7.71B+10.1% | $7.01B+5.8% | $6.62B+11.6% | $5.93B+45.1% | ||
| $4.9B-5.2% | $5.17B-4.9% | $5.43B-1.6% | $5.52B-1.1% | $5.58B-0.2% | ||
| $484M-2.0% | $494M-1.8% | $503M-1.8% | $512M0.0% | $512M-3.4% | ||
| -$647M+10.3% | -$721M+30.4% | -$1.04B+7.2% | -$1.12B-3.6% | -$1.08B+12.3% | ||
| —— | —— | —— | —— | $891M+460% | ||
| $1.18B-59.4% | $2.9B+115% | $1.35B-20.2% | $1.69B— | —— | ||
| -$616M+30.5% | -$886M+18.7% | -$1.09B+28.8% | -$1.53B+24.0% | -$2.01B+20.5% | ||
| —— | —— | —— | —— | —— | ||
| $414M-17.0% | $499M+4.4% | $478M+18.6% | $403M+48.2% | $272M+196% | ||
| $1.06B-16.5% | $1.27B+80.0% | $704M-2.2% | $720M-5.8% | $764M+17.2% | ||
| -$161M+1.8% | -$164M— | —— | —— | —— | ||
| -$132M+11.4% | -$149M-207% | $139M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $1.65B+1,138% | ||
| $10.76B+8.0% | $9.96B-24.1% | $13.13B+9.3% | $12.01B-1.5% | $12.19B+6.1% | ||
| $2.16B+16.2% | $1.86B+17.1% | $1.59B+12.7% | $1.41B+10.3% | $1.28B+16.5% | ||
| —— | —— | —— | —— | —— | ||
| -$2.21B-13.8% | -$1.94B-17.6% | -$1.65B-14.1% | -$1.45B-13.5% | -$1.28B-22.0% | ||
| $5.2B+1.5% | $5.12B+1.5% | $5.05B+1.4% | $4.97B+1.4% | $4.9B+1.5% | ||
| —— | —— | —— | —— | $0— | ||
| $3.33B-33.3% | $5B0.0% | $5B-12.3% | $5.7B-6.6% | $6.1B+69.4% | ||
| —— | —— | —— | -$121M-75.4% | -$69M+47.7% | ||
| -$5.32B+51.0% | -$10.86B+1.6% | -$11.04B+6.7% | -$11.84B-0.2% | -$11.81B-25.5% | ||
| —— | —— | —— | -$1.27B-41.8% | -$898M-187% | ||
| —— | —— | $2.96B+9.4% | $2.7B+35.3% | $2B+67.2% | ||
| $312M+0.3% | $311M— | —— | —— | —— | ||
| $1.06B-16.5% | $1.27B+80.0% | $704M-2.2% | $720M-5.8% | $764M+17.2% | ||
| -$132M+11.4% | -$149M-207% | $139M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $615M-10.0% | $683M— | —— | —— | —— | ||
| —— | —— | —— | -$121M-75.4% | -$69M+47.7% | ||
| —— | —— | —— | —— | $1.65B+1,138% | ||
| $8.6B+6.1% | $8.1B-29.8% | $11.54B+8.8% | $10.61B-2.8% | $10.92B+5.0% | ||
| $8.6B+6.1% | $8.1B-29.8% | $11.54B+8.8% | $10.61B-2.8% | $10.92B+5.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amgen generate?
- Amgen (AMGN) generated $10.8B in operating cash flow over the trailing twelve months.
- What is Amgen's free cash flow?
- After $2.2B of capital expenditures, Amgen's free cash flow was $8.6B over the trailing twelve months, down 21.2% year over year.
- Where does Amgen's cash flow data come from?
- Every line is extracted from Amgen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
